Plain-English translation of NCT01749540 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Thalassemia research guide βPhase 2 β Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested a medication called to see if it could help people with beta-thalassemia, a blood disorder where the body doesn't make enough healthy red blood cells. Researchers studied different doses of the medication to find what works best and is safest. The goal was to help patients either increase their hemoglobin (a protein in red blood cells that carries oxygen) or reduce how often they needed blood transfusions.
Beta-thalassemia patients often depend on regular blood transfusions to survive, which can cause serious complications over time. This trial aimed to find out whether this medication could help the body produce more of its own healthy red blood cells, potentially reducing the need for transfusions.
Participants received injections of the medication under the skin once every three weeks for up to five cycles (about three-and-a-half months total). The trial tested six different dose levels, with each group of participants receiving a specific dose. Throughout the study, participants had regular blood tests to measure their hemoglobin levels and monitor how well the medication was working and whether it was safe.
AI-generated summary from trial data Β· Aug 22, 2026 Β· Not medical advice
Greece
Italy